Previous Close | 105.84 |
Open | 105.12 |
Bid | 105.32 x 800 |
Ask | 105.33 x 900 |
Day's Range | 105.11 - 106.55 |
52 Week Range | 85.67 - 119.65 |
Volume | |
Avg. Volume | 6,912,519 |
Market Cap | 267.493B |
Beta (5Y Monthly) | 0.33 |
PE Ratio (TTM) | 86.41 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 2.92 (2.76%) |
Ex-Dividend Date | Sept 14, 2023 |
1y Target Est | N/A |
Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints.
The FDA grants priority review to Merck's (MRK) sBLA seeking expanded use of Keytruda for an earlier stage of cervical cancer disease.
The FDA filing is supported by data from a late-stage study that shows that Merck's (MRK) Welireg achieved statistically significant and clinically meaningful improvement in progression-free survival.